Основная статистика
| LEI | 8MYN82XMYQH89CTMTH67 |
| CIK | 1156039 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Anthem Inc
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 4, 2025 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commiss |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 28, 2025 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation or organization) ( |
|
| July 28, 2025 |
Elevance Health Board Welcomes Steve Collis as New Director, Reflecting Ongoing Commitment to Governance Excellence INDIANAPOLIS – July 28, 2025 – The board of directors of Elevance Health (NYSE: ELV) announced today that Steve Collis, a highly regarded global healthcare executive, will be joining the company’s board, effective August 1. |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 17, 2025 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commission |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE H |
|
| July 17, 2025 |
ealth Board of Directors Compensa ELEVANCE HEALTH, INC. BOARD OF DIRECTORS COMPENSATION PROGRAM (AS AMENDED EFFECTIVE May 14, 2025) Directors who are employed by Elevance Health, Inc. or its subsidiaries do not receive compensation for serving as Directors. However, Directors who are not employees of Elevance Health, Inc. or its subsidiaries are entitled to receive the following compensation: CASH COMPENSATION—Retainers Annual Boa |
|
| July 17, 2025 |
E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS SECOND QUARTER 2025 RESULTS E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS SECOND QUARTER 2025 RESULTS •2Q 2025 operating revenue of $49. |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 A. Full title of the plan |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 A. Full title of the plan |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2025 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commission F |
|
| May 14, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2025 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commission F |
|
| April 22, 2025 |
E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS FIRST QUARTER 2025 RESULTS E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS FIRST QUARTER 2025 RESULTS •1Q 2025 operating revenue of $48. |
|
| April 22, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 22, 2025 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commission |
|
| April 22, 2025 |
Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 202 EXHIBIT 10.2(q) Schedule A Notice of Option Grant Participant: [] Company: Elevance Health, Inc. Notice: You have been granted the following nonqualified stock option to purchase shares of common stock of the Company in accordance with the terms of the Plan and the attached Nonqualified Stock Option Award Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [] Grant |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE |
|
| April 22, 2025 |
Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 202 EXHIBIT 10.2(s) Schedule A Notice of Performance Stock Unit Grant Participant: [] Company: Elevance Health, Inc. Notice: You have been granted the following award of performance stock units of common stock of the Company in accordance with the terms of the Plan and the attached Performance Stock Unit Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [] Grant Numb |
|
| April 22, 2025 |
Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 202 EXHIBIT 10.2(r) Schedule A Notice of Restricted Stock Unit Grant Participant: [] Company: Elevance Health, Inc. Notice: You have been granted the following award of restricted stock units of common stock of the Company in accordance with the terms of the Plan and the attached Restricted Stock Unit Award Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [] Grant N |
|
| April 17, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 17, 2025 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commission |
|
| April 14, 2025 |
Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of Registrant: Elevance Health Inc (ELV) Name of person relying on exemption: As You Sow® Address of persons relying on exemption: 11461 San Pablo Ave, Suite 400, El Cerrito, CA 94530 The attached written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. |
|
| March 28, 2025 |
a2025defa14aproxynotice Step 1: Go to www.envisionreports.com/elv Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/elv Online Go to www.envisionreports.com/elv or scan the QR code — login details are located in the shaded bar below. Shareholder Meeting Notice 0438HE Important Notice Regarding the Availability of |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2025 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation or organization) |
|
| February 20, 2025 |
Exhibit 21 Listed below are subsidiaries of Elevance Health, Inc. as of February 1, 2025 with ownership of 50% and above. Entity Name Domestic Jurisdiction Doing Business As 4600 Group, LLC California 4600BOEHM 4600 Group Holdings, LLC California Advantage Medical Group, LLC Puerto Rico Alianza Medicos del SurEste, LLC Puerto Rico Alliance Care Management, LLC Delaware Amerigroup Mississippi, Inc. |
|
| February 20, 2025 |
EXHIBIT 10.12 BLUE CROSS LICENSE AGREEMENT (Includes revisions, if any, adopted by Member Plans through their September 19, 2024, meeting) This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Cross Plan, known as (the "Plan"). Preamble WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE CROSS and BLU |
|
| February 20, 2025 |
, Inc. Insider Trading Policy, last amen EXHIBIT 19.1 INSIDER TRADING POLICY 1.Introduction This Insider Trading Policy (this “Policy”) provides guidelines to all directors, officers and associates of Elevance Health, Inc. and its subsidiaries (together referred to as “Elevance Health” or the “Company”) with respect to transactions in Elevance Health’s common stock and other securities. You are individually responsible for complying with |
|
| February 20, 2025 |
EXHIBIT 10.13 BLUE SHIELD LICENSE AGREEMENT (Includes revisions, if any, adopted by Member Plans through their September 19, 2024 meeting) This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Shield Plan, known as (the "Plan"). Preamble WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE SHIELD and B |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE HEALT |
|
| January 23, 2025 |
E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS; SETS FULL YEAR 2025 OUTLOOK •4Q 2024 operating revenue of $45. |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 23, 2025 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commissi |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 (October 22, 2024) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorpora |
|
| October 31, 2024 |
Form of the 5.200% Notes due 2035 Exhibit 4.5 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANC |
|
| October 31, 2024 |
Form of the 4.750% Notes due 2030 Exhibit 4.3 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANC |
|
| October 31, 2024 |
Form of the 4.500% Notes due 2026 Exhibit 4.2 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANC |
|
| October 31, 2024 |
Exhibit 1.1 Elevance Health, Inc. $350,000,000 4.500% Notes due 2026 $750,000,000 4.750% Notes due 2030 $750,000,000 4.950% Notes due 2031 $1,200,000,000 5.200% Notes due 2035 $1,350,000,000 5.700% Notes due 2055 $800,000,000 5.850% Notes due 2064 UNDERWRITING AGREEMENT Dated: October 22, 2024 TABLE OF CONTENTS Page SECTION 1. Representations and Warranties. 2 SECTION 2. Sale and Delivery to Under |
|
| October 31, 2024 |
Form of the 5.850% Notes due 2064 Exhibit 4.7 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANC |
|
| October 31, 2024 |
Form of the 5.700% Notes due 2055 Exhibit 4.6 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANC |
|
| October 31, 2024 |
Form of the 4.950% Notes due 2031 Exhibit 4.4 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANC |
|
| October 23, 2024 |
PROSPECTUS SUPPLEMENT (To Prospectus dated November 1, 2023) TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-275251 PROSPECTUS SUPPLEMENT (To Prospectus dated November 1, 2023) $5,200,000,000 $350,000,000 4.500% Notes due 2026 $750,000,000 4.750% Notes due 2030 $750,000,000 4.950% Notes due 2031 $1,200,000,000 5.200% Notes due 2035 $1,350,000,000 5.700% Notes due 2055 $800,000,000 5.850% Notes due 2064 The 4.500% Notes due 2026, wh |
|
| October 23, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) Elevance Health, Inc. |
|
| October 22, 2024 |
Free Writing Prospectus Filed Pursuant to Rule 433 To Prospectus dated November 1, 2023 Preliminary Prospectus Supplement dated October 22, 2024 Registration Statement File No. |
|
| October 22, 2024 |
TABLE OF CONTENTS This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. |
|
| October 17, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 17, 2024 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commissi |
|
| October 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVA |
|
| October 17, 2024 |
E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS THIRD QUARTER 2024 RESULTS E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS THIRD QUARTER 2024 RESULTS •3Q 2024 operating revenue of $44. |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE H |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 17, 2024 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commission |
|
| July 17, 2024 |
E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS SECOND QUARTER 2024 RESULTS E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS SECOND QUARTER 2024 RESULTS •2Q 2024 operating revenue of $43. |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 A. Full title of the plan |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 12, 2024 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commission |
|
| May 30, 2024 |
EX-1.1 Exhibit 1.1 Elevance Health, Inc. $600,000,000 5.150% Notes due 2029 $1,000,000,000 5.375% Notes due 2034 $1,000,000,000 5.650% Notes due 2054 UNDERWRITING AGREEMENT Dated: May 20, 2024 TABLE OF CONTENTS Page SECTION 1. Representations and Warranties 2 SECTION 2. Sale and Delivery to Underwriters; Closing 11 SECTION 3. Covenants of the Company 12 SECTION 4. Payment of Expenses 15 SECTION 5. |
|
| May 30, 2024 |
to the Company's Current Report on Form 8-K filed on May 30, 2024. EX-4.3 Exhibit 4.3 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRC |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 (May 20, 2024) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (C |
|
| May 30, 2024 |
ference to Exhibit 4.2 to the Company's Current R EX-4.2 Exhibit 4.2 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRC |
|
| May 30, 2024 |
EX-4.4 Exhibit 4.4 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRC |
|
| May 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) Elevance Health, Inc. |
|
| May 21, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-275251 PROSPECTUS SUPPLEMENT (To Prospectus dated November 1, 2023) $2,600,000,000 $600,000,000 5.150% Notes due 2029 $1,000,000,000 5.375% Notes due 2034 $1,000,000,000 5.650% Notes due 2054 The 5.150% Notes due 2029, which we refer to as the 2029 notes, will mature on June 15, 2029, the 5.375% Notes due 2034, which we refer |
|
| May 20, 2024 |
Free Writing Prospectus Filed Pursuant to Rule 433 To Prospectus dated November 1, 2023 Preliminary Prospectus Supplement dated May 20, 2024 Registration Statement File No. |
|
| May 20, 2024 |
Table of Contents This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 15, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2024 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commission F |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 18, 2024 |
Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2024. EXHIBIT 10.2(r) Schedule A Notice of Performance Stock Unit Grant Participant: [●] Company: Elevance Health, Inc. Notice: You have been granted the following award of performance stock units of common stock of the Company in accordance with the terms of the Plan and the attached Performance Stock Unit Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [●] Grant Nu |
|
| April 18, 2024 |
Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2024. EXHIBIT 10.2(q) Schedule A Notice of Restricted Stock Unit Grant Participant: [●] Company: Elevance Health, Inc. Notice: You have been granted the following award of restricted stock units of common stock of the Company in accordance with the terms of the Plan and the attached Restricted Stock Unit Award Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [●] Grant |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE |
|
| April 18, 2024 |
EARNINGS RELEASE ELEVANCE HEALTH REPORTS FIRST QUARTER 2024 RESULTS Exhibit 99.1 EARNINGS RELEASE ELEVANCE HEALTH REPORTS FIRST QUARTER 2024 RESULTS • 1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 • 1Q 2024 diluted EPS1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS2 of $10.64, up 12.5% • FY 2024 diluted EPS and adjusted diluted EPS guidance raised to greater than $34.05 and $37.20, respectively • Launching strategic partnership to adv |
|
| April 18, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 18, 2024 |
Elevance Health Executive Agreement Plan, as amended and restated effective March 1, 2024. EXHIBIT 10.4 Elevance Health EXECUTIVE AGREEMENT PLAN (Amended and Restated as of March 1, 2024) TABLE OF CONTENTS ARTICLE 1 PURPOSE AND INTENT 1 1.1 Purpose and Intent 1 ARTICLE 2 ELIGIBILITY AND PARTICIPATION 1 2.1 Participation 1 2.2 Termination of Participation 1 ARTICLE 3 SEVERANCE BENEFITS 2 3.1 Eligible Separation from Service 2 3.2 Severance Pay 2 3.3 Other Benefits During Severance Period |
|
| April 18, 2024 |
Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2024. EXHIBIT 10.2(p) Schedule A Notice of Option Grant Participant: [●] Company: Elevance Health, Inc. Notice: You have been granted the following nonqualified stock option to purchase shares of common stock of the Company in accordance with the terms of the Plan and the attached Nonqualified Stock Option Award Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [●] Gra |
|
| March 29, 2024 |
-34>7A8 A@F7@FE 8EKJ!B;L7D9;$;7BJ> !B;L7D9;$;7BJ>?I7B?<;J?C; JHKIJ;:>;7BJ>F7HJD;H;>;7BJ>E<>KC7D?JO3; IKFFEHJ9EDIKC;HI <7C?B?;I7D:9ECCKD?J?;I79HEIIJ>; ;DJ?H;97H;@EKHD;OT9EDD;9J?D=J>;CJEJ>;97H; IKFFEHJ 7D:H;IEKH9;IJ>;OD;;:JEB;7:>;7BJ>?;HB?L;I+KH 9ECF7D?;II;HL;CEH;J>7DC?BB?EDF;EFB;J>HEK=>7 :?L;HI;FEHJ<?D:KIJHO B;7:?D=C;:?97B :?=?J7B F>7 |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 4, 2024 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation or organization) ( |
|
| February 23, 2024 |
Exhibit 99.1 ELEVANCE HEALTH PUERTO RICO RETIREMENT PLAN Amended and Restated Effective as of January 1, 2024 Table of Contents Page ARTICLE I INTRODUCTION 1 ARTICLE II DEFINITIONS AND CONSTRUCTION 1 ARTICLE III PARTICIPATION AND SERVICE 12 3.1 Participation 12 3.2 Change in Active Status 12 3.3 Special Rules for Participation and Vesting Purposes 12 3.4 Participation and Service upon Reemployment |
|
| February 23, 2024 |
As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration No. |
|
| February 23, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Elevance Health, Inc. |
|
| February 23, 2024 |
Amendment #1 to Elevance Health Puerto Rico Retirement Plan, effective February 20, 2024* Exhibit 99.2 AMENDMENT #1 TO ELEVANCE HEALTH PUERTO RICO RETIREMENT PLAN Pursuant to authority delegated by the Board of Managers of ATH Holding Company, LLC (the “Company”), the Elevance Health Puerto Rico Retirement Plan (the “Plan”), as amended and restated effective January 1, 2024, is hereby further amended, effective February 20, 2024, as follows: 1. The Plan is amended to add the Elevance H |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE HEALT |
|
| February 21, 2024 |
Exhibit 10.12 BLUE CROSS LICENSE AGREEMENT (Includes revisions, if any, adopted by Member Plans through their November 16, 2023 meeting) This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Cross Plan, known as(the "Plan"). Preamble WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE CROSS and BLUE C |
|
| February 21, 2024 |
Exhibit 21 Listed below are subsidiaries of Elevance Health, Inc. as of February 1, 2024 with ownership of 50% and above. Entity Name Domestic Jurisdiction Doing Business As Advantage Medical Group, LLC Puerto Rico Alianza Medicos del SurEste, LLC Puerto Rico Alliance Care Management, LLC Delaware AMERIGROUP Community Care of New Mexico, Inc. New Mexico Amerigroup District of Columbia, Inc. Distri |
|
| February 21, 2024 |
Exhibit 10.13 BLUE SHIELD LICENSE AGREEMENT (Includes revisions, if any, adopted by Member Plans through their November 16, 2023 meeting) This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Shield Plan, known as (the "Plan"). Preamble WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE SHIELD and BL |
|
| February 21, 2024 |
Exhibit 97 Elevance Health, Inc. Incentive Compensation Recoupment Policy I. Introduction. The Board of Directors of Elevance Health, Inc. (the “Company”) believes that it is in the best interest of the Company and its shareholders to create and maintain a culture that emphasizes trustworthiness and accountability, demonstrates good leadership, and reinforces the Company’s pay-for-performance comp |
|
| February 21, 2024 |
Exhibit 10.3 ELEVANCE HEALTH COMPREHENSIVE NON-QUALIFIED DEFERRED COMPENSATION PLAN (AS AMENDED AND RESTATED EFFECTIVE JANUARY 1, 2024) Exhibit 10.3 TABLE OF CONTENTS Page ARTICLE I HISTORY AND PURPOSE 1 1.01 History 1 1.02 Purpose 2 ARTICLE II DEFINITIONS 2 2.01 “Account” 2 2.02 “Administrator” 3 2.03 “Affiliate” 3 2.04 “Anthem LTIP” 3 2.05 “Anthem Plan” 3 2.06 “Anthem SERP” 3 2.07 “Anthem SERP P |
|
| February 13, 2024 |
ELV / Elevance Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0825-elevancehealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Elevance Health Inc Title of Class of Securities: Common Stock CUSIP Number: 036752103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designa |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 25, 2024 (January 23, 2024) Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporat |
|
| January 24, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 24, 2024 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation or organization |
|
| January 24, 2024 |
Exhibit 99.1 E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS RESULTS FOR FOURTH QUARTER AND FULL YEAR 2023; SETS FULL YEAR 2024 OUTLOOK • 4Q 2023 operating revenue of $42.5 billion, up 7.0% from 4Q 2022; FY 2023 operating revenue of $170 billion, up 9.3% from FY 2022 • 4Q 2023 GAAP diluted EPS1 of $3.63, up 1.1% from 4Q 2022 and adjusted diluted EPS2 of $5.62, up 15.2%; FY 2023 GAAP diluted |
|
| November 1, 2023 |
Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) ☐ The Bank of New York Mellon Trust Company, N.A. (Exact name of trustee as specified in its charter) N/A |
|
| November 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Elevance Health, Inc. |
|
| November 1, 2023 |
As filed with the Securities and Exchange Commission on November 1, 2023 As filed with the Securities and Exchange Commission on November 1, 2023 Registration No. |
|
| October 18, 2023 |
Exhibit 10.9(d) EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (the “Agreement”) dated as of (the “Agreement Date”), between Elevance Health Inc., an Indiana corporation (“Elevance Health”) with its headquarters and principal place of business in Indianapolis, Indiana (Elevance Health, together with its subsidiaries and affiliates are collectively referred to herein as the “Company”), and the person li |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 18, 2023 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation or organization |
|
| October 18, 2023 |
EXHIBIT 99.1 EXPLANATORY NOTE Elevance Health, Inc. (“we,” “our,” “us,” “Elevance Health” or the “Company”) is filing this Exhibit 99.1 to this Quarterly Report on Form 10-Q to recast certain financial information and related disclosures included in Part I, Item 1 “Business,” Part II Item 7 “Management's Discussion and Analysis of Financial Condition and Results of Operations,” Part II Item 8 “Fin |
|
| October 18, 2023 |
ELEVANCE HEALTH REPORTS THIRD QUARTER 2023 RESULTS EX-99.1 Exhibit 99.1 ELEVANCE HEALTH REPORTS THIRD QUARTER 2023 RESULTS • Third quarter GAAP net income was $5.45 per share, including net negative adjustment items of $3.54 per share. Adjusted net income was $8.99* per share. • Operating gain, excluding adjustment items, grew 12.6% year-over-year to $2.5 billion. • Operating cash flow was $2.6 billion. Indianapolis, Ind. - October 18, 2023 - Elev |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVA |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 13, 2023 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation or organization |
|
| October 5, 2023 |
BYLAWS OF ELEVANCE HEALTH, INC. (As Amended October 4, 2023) ARTICLE I Meetings of Shareholders Section 1.1 Annual Meetings. Annual meetings of the shareholders of the Corporation shall be held each year on such date, at such hour and at such place, if any, within or without the State of Indiana, or may be held solely by means of remote communication, as shall be designated by the Board of Directo |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 5, 2023 (October 4, 2023) Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 00 |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 20, 2023 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation or organizati |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2023 (August 2, 2023) Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation |
|
| August 8, 2023 |
EX-10.1 Exhibit 10.1 August 2, 2023 Mark Kaye Sent Via Email Dear Mark: On behalf of the Board and me, I am pleased to provide the following offer of employment to you as Chief Financial Officer reporting to Gail Boudreaux. This position will be based out of our 220 Virginia Avenue, Indianapolis, Indiana office and your start date will be September 6, 2023. You will be CFO Designate from your star |
|
| August 8, 2023 |
EX-99.1 Exhibit 99.1 Elevance Health Announces John Gallina to Retire as CFO Mark Kaye named Executive Vice President, Chief Financial Officer INDIANAPOLIS— August 8, 2023 – Elevance Health (NYSE: ELV) announced today that John Gallina will retire from his role as executive vice president and CFO later this year. Mark Kaye has been named executive vice president and CFO and will serve as a member |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE H |
|
| July 19, 2023 |
Exhibit 10.7 ELEVANCE HEALTH, INC. BOARD OF DIRECTORS COMPENSATION PROGRAM (AS AMENDED EFFECTIVE MAY 10, 2023) Directors who are employed by Elevance Health, Inc. or its subsidiaries do not receive compensation for serving as Directors. However, Directors who are not employees of Elevance Health, Inc. or its subsidiaries are entitled to receive the following compensation: CASH COMPENSATION—Retaine |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File |
|
| July 19, 2023 |
P R E S S R E L E A S E ELEVANCE HEALTH REPORTS SECOND QUARTER 2023 RESULTS EX-99.1 Exhibit 99.1 P R E S S R E L E A S E ELEVANCE HEALTH REPORTS SECOND QUARTER 2023 RESULTS • Second quarter GAAP net income was $7.79 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $9.04* per share. • Operating revenue grew 12.7% year-over-year to $43.4 billion • Operating gain grew 12.0% year-over-year to $2.6 billion • Medical enrollment incr |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 A. Full title of the plan |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 13, 2023 Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-16751 (Commission |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2023 (May 10, 2023) Date of Report (Date of earliest event reported) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation or organization) 001-1675 |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 19, 2023 |
eport on Form 10-Q for the quarter ended March 31, 2023. EXHIBIT 10.2(o) Schedule A Notice of Option Grant Participant: [●] Company: Elevance Health, Inc. Notice: You have been granted the following nonqualified stock option to purchase shares of common stock of the Company in accordance with the terms of the Plan and the attached Nonqualified Stock Option Award Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [●] Gra |
|
| April 19, 2023 |
Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2023. EXHIBIT 10.2(q) Schedule A Notice of Performance Stock Unit Grant Participant: [●] Company: Elevance Health, Inc. Notice: You have been granted the following award of performance stock units of common stock of the Company in accordance with the terms of the Plan and the attached Performance Stock Unit Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [●] Grant Nu |
|
| April 19, 2023 |
ELEVANCE HEALTH REPORTS FIRST QUARTER 2023 RESULTS EX-99.1 Exhibit 99.1 ELEVANCE HEALTH REPORTS FIRST QUARTER 2023 RESULTS • First quarter GAAP net income was $8.30 per share, including net negative adjustment items of $1.16 per share. Adjusted net income was $9.46* per share. • Operating revenue grew 10.6% year-over-year to $41.9 billion • Operating gain grew 16.6% year-over-year to $2.8 billion • Medical enrollment increased 1.3 million members |
|
| April 19, 2023 |
Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2023. EXHIBIT 10.2(p) Schedule A Notice of Restricted Stock Unit Grant Participant: [●] Company: Elevance Health, Inc. Notice: You have been granted the following award of restricted stock units of common stock of the Company in accordance with the terms of the Plan and the attached Restricted Stock Unit Award Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [●] Grant |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE |
|
| March 31, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 (February 15, 2023) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorpo |
|
| February 15, 2023 |
Exhibit 21 SUBSIDIARIES OF THE COMPANY Legal Name Domestic Jurisdiction Doing Business As Advantage Medical Group, LLC Puerto Rico Alianza Medicos del SurEste, LLC Puerto Rico Alliance Care Management, LLC Delaware American Imaging Management, Inc. |
|
| February 15, 2023 |
Elevance Health Incentive Compensation Plan, as amended and restated effective June 28, 2022 Exhibit 10.1 EXHIBIT A 2014 ELEVANCE HEALTH INCENTIVE COMPENSATION PLAN (2022 RESTATEMENT) Elevance Health, Inc., an Indiana corporation formerly known as Anthem, Inc. (the “Company”) previously adopted the Anthem Incentive Compensation Plan (formerly named, the “WellPoint Incentive Compensation Plan”), which it hereby amends and restates as the 2014 Elevance Health Incentive Compensation Plan (20 |
|
| February 15, 2023 |
Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The common stock of Elevance Health, Inc. (“Elevance Health,” “we,” “our,” or “us”) is the only class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following is a summary of the general terms and pro |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE HEALT |
|
| February 15, 2023 |
Exhibit 10.12 BLUE SHIELD LICENSE AGREEMENT (Includes revisions, if any, adopted by Member Plans through their June 16, 2022 meeting) This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Shield Plan, known as (the "Plan"). Preamble WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE SHIELD and BLUE S |
|
| February 15, 2023 |
Exhibit 10.11 BLUE CROSS LICENSE AGREEMENT (Includes revisions, if any, adopted by Member Plans through their June 16, 2022 meeting) This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Cross Plan, known as (the "Plan"). Preamble WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE CROSS and BLUE CROS |
|
| February 9, 2023 |
ANTM / Anthem Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Elevance Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 036752103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 8, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 (January 30, 2023) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorpora |
|
| February 8, 2023 |
Form of 5.125% Notes due 2053, incorporated by reference to Exhibit 4.3 to the Company Exhibit 4.3 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANC |
|
| February 8, 2023 |
Form of 4.900% Notes due 2026, incorporated by reference to Exhibit 4.1 to the Company Exhibit 4.1 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANC |
|
| February 8, 2023 |
Form of 4.750% Notes due 2033, incorporated by reference to Exhibit 4.2 to the Company Exhibit 4.2 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANC |
|
| February 8, 2023 |
EX-1.1 2 d413102dex11.htm EX-1.1 Exhibit 1.1 Execution Version Elevance Health, Inc. $500,000,000 4.900% Notes due 2026 $1,000,000,000 4.750% Notes due 2033 $1,100,000,000 5.125% Notes due 2053 UNDERWRITING AGREEMENT Dated: January 30, 2023 TABLE OF CONTENTS Page SECTION 1. Representations and Warranties 2 SECTION 2. Sale and Delivery to Underwriters; Closing 11 SECTION 3. Covenants of the Company |
|
| February 1, 2023 |
EX-FILING FEES 2 d427160dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) Elevance Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggr |
|
| February 1, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-249877 Prospectus Supplement (To Prospectus dated November 5, 2020) $2,600,000,000 $500,000,000 4.900% Notes due 2026 $1,000,000,000 4.750% Notes due 2033 $1,100,000,000 5.125% Notes due 2053 The 4.900% Notes due 2026, which we refer to as the 2026 notes, will mature on February 8, 2026, the 4.750% Notes due 2033, which we ref |
|
| January 30, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-249877 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. SUBJECT TO COMPLETION, DATED JANUARY 30, 2023 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus dated No |
|
| January 30, 2023 |
Free Writing Prospectus Filed Pursuant to Rule 433 To Prospectus dated November 5, 2020 Preliminary Prospectus Supplement dated January 30, 2023 Registration Statement File No. |
|
| January 25, 2023 |
ELEVANCE HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS Exhibit 99.1 PRESS RELEASE ELEVANCE HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS • Fourth quarter and full year GAAP net income was $3.93 and $24.81 per share • Fourth quarter and full year adjusted net income was $5.23* and $29.07* per share • Full year operating revenue grew 13.7% year-over-year to $156 billion • Full year operating gain grew 12.9% year-over-year to $8.5 billion • Me |
|
| January 25, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission F |
|
| November 15, 2022 |
GOCO / GoHealth, Inc. Class A / Anthem, Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GoHealth, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 38046W105 (CUSIP Number) September 23, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| November 15, 2022 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to certain shares of the Class A common stock of GoHealth, Inc. and further agree that this Joint Filing Agreement shall be i |
|
| November 4, 2022 |
Exhibit 1.1 Execution Version Elevance Health, Inc. $400,000,000 5.350% Notes due 2025 $650,000,000 5.500% Notes due 2032 $750,000,000 6.100% Notes due 2052 UNDERWRITING AGREEMENT Dated: October 26, 2022 TABLE OF CONTENTS Page SECTION 1. Representations and Warranties 2 SECTION 2. Sale and Delivery to Underwriters; Closing 11 SECTION 3. Covenants of the Company 12 SECTION 4. Payment of Expenses 15 |
|
| November 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 (October 26, 2022) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorpora |
|
| November 4, 2022 |
Exhibit 4.2 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANC |
|
| November 4, 2022 |
EX-4.1 3 d416104dex41.htm EX-4.1 Exhibit 4.1 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO |
|
| November 4, 2022 |
EX-4.3 5 d416104dex43.htm EX-4.3 Exhibit 4.3 ELEVANCE HEALTH, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO |
|
| October 27, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-249877 PROSPECTUS SUPPLEMENT (To Prospectus dated November 5, 2020) $1,800,000,000 $400,000,000 5.350% Notes due 2025 $650,000,000 5.500% Notes due 2032 $750,000,000 6.100% Notes due 2052 The 5.350% Notes due 2025, which we refer to as the 2025 notes, will mature on October 15, 2025, the 5.500% Notes due 2032, which we refer t |
|
| October 27, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) Elevance Health, Inc. |
|
| October 26, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-249877 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. SUBJECT TO COMPLETION, DATED OCTOBER 26, 2022 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus dated No |
|
| October 26, 2022 |
Free Writing Prospectus Filed Pursuant to Rule 433 To Prospectus dated November 5, 2020 Preliminary Prospectus Supplement dated October 26, 2022 Registration Statement File No. |
|
| October 25, 2022 |
Elevance Health Board Welcomes Deanna Strable as New Director Exhibit 99.1 Elevance Health Board Welcomes Deanna Strable as New Director INDIANAPOLIS ? October 25, 2022 ? The Board of Directors of Elevance Health (NYSE: ELV) announced that Deanna Strable will be joining the Board. She will serve on the Audit and Governance Committees. With a career spanning more than three decades at a Fortune 500 global financial services company, Ms. Strable currently serv |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 (October 24, 2022) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorpora |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVA |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission F |
|
| October 19, 2022 |
ELEVANCE HEALTH REPORTS THIRD QUARTER 2022 RESULTS, RAISES FULL YEAR OUTLOOK Exhibit 99.1 PRESS RELEASE ELEVANCE HEALTH REPORTS THIRD QUARTER 2022 RESULTS, RAISES FULL YEAR OUTLOOK ? Third quarter GAAP net income was $6.68 per share, including net negative adjustment items of $0.85 per share. Adjusted net income was $7.53* per share. ? Operating revenue grew 11.5% over the prior year quarter to $39.6 billion. ? Operating gain grew 10.2% over the prior year quarter to $2.3 |
|
| July 20, 2022 |
EXHIBIT 10.7 ELEVANCE HEALTH, INC. BOARD OF DIRECTORS COMPENSATION PROGRAM (AS AMENDED EFFECTIVE JUNE 28, 2022) Directors who are employed by Elevance Health, Inc. or its subsidiaries do not receive compensation for serving as Directors. However, Directors who are not employees of Elevance Health, Inc. or its subsidiaries are entitled to receive the following compensation: CASH COMPENSATION?Retain |
|
| July 20, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2022 Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File |
|
| July 20, 2022 |
Exhibit 10.6 Summary of the Elevance Health, Inc. Directed Executive Compensation (DEC) Program (effective June 28, 2022) Directed Executive Compensation (DEC) is an executive perquisite plan that provides officers of Elevance Health, Inc. (the ?Company?) with flexibility to tailor certain benefits to meet their needs with a combination of cash (Cash Credits) and reimbursement of allowable expense |
|
| July 20, 2022 |
EXHIBIT 10.8 ELEVANCE HEALTH BOARD OF DIRECTORS? DEFERRED COMPENSATION PLAN As Amended and Restated Effective June 28, 2022 EXHIBIT 10.8 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 3 Section 1.01 Administrator 3 Section 1.02 Beneficiary 3 Section 1.03 Cash Participation Account 3 Section 1.04 Company 3 Section 1.05 Company Common Stock 3 Section 1.06 Compensation 3 Section 1.07 Director 3 Section |
|
| July 20, 2022 |
ELEVANCE HEALTH REPORTS SECOND QUARTER 2022 RESULTS, RAISES FULL YEAR OUTLOOK Exhibit 99.1 ELEVANCE HEALTH REPORTS SECOND QUARTER 2022 RESULTS, RAISES FULL YEAR OUTLOOK ? Second quarter GAAP net income was $6.79 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $8.04* per share. ? Operating revenue grew 15.6% over the prior year quarter to $38.5 billion. ? Operating gain grew 13.7% over the prior year quarter to $2.4 billion. ? M |
|
| July 20, 2022 |
EXHIBIT 10.2(n) Schedule A Notice of Performance Stock Unit Grant Participant: [?] Company: Elevance Health, Inc. Notice: You have been granted the following award of performance stock units of common stock of the Company in accordance with the terms of the Plan and the attached Performance Stock Unit Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [?] Grant Nu |
|
| July 20, 2022 |
EXHIBIT 10.2(l) Schedule A Notice of Option Grant Participant: [?] Company: Elevance Health, Inc. Notice: You have been granted the following nonqualified stock option to purchase shares of common stock of the Company in accordance with the terms of the Plan and the attached Nonqualified Stock Option Award Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [?] Gra |
|
| July 20, 2022 |
EXHIBIT 10.5 Elevance Health Executive Salary Continuation Plan Amended and Restated Effective June 28, 2022 EXHIBIT 10.5 Article 1: Definitions Capitalized terms used in the Plan have the following meanings: 1.1 ?Authorized Health Care Provider? means a person who is licensed to practice medicine and such other persons as are included by operation of state law. In no circumstances will a family m |
|
| July 20, 2022 |
Elevance Health Executive Agreement Plan, as amended and restated effective June 28, 2022. EXHIBIT 10.4 Elevance Health EXECUTIVE AGREEMENT PLAN (Amended and Restated Effective June 28, 2022) EXHIBIT 10.4 TABLE OF CONTENTS Article 1 ESTABLISHMENT, AMENDMENT, PURPOSE AND INTENT 1 1.1 Establishment, Amendment, Purpose and Intent 1 Article 2 ELIGIBILITY AND PARTICIPATION 1 2.1 Participation 1 2.2 Termination of Participation 1 2.3 Employment Period 2 Article 3 SEVERANCE BENEFITS 2 3.1 Elig |
|
| July 20, 2022 |
EXHIBIT 10.2(m) Schedule A Notice of Restricted Stock Unit Grant Participant: [?] Company: Elevance Health, Inc. Notice: You have been granted the following award of restricted stock units of common stock of the Company in accordance with the terms of the Plan and the attached Restricted Stock Unit Award Agreement. Plan: 2017 Elevance Health Incentive Compensation Plan Grant: Grant Date: [?] Grant |
|
| July 20, 2022 |
EXHIBIT 10.3 ELEVANCE HEALTH COMPREHENSIVE NON-QUALIFIED DEFERRED COMPENSATION PLAN (AS AMENDED AND RESTATED EFFECTIVE JUNE 28, 2022) EXHIBIT 10.3 TABLE OF CONTENTS Page ARTICLE I HISTORY AND PURPOSE 1 1.01 History 1 1.02 Purpose 2 ARTICLE II DEFINITIONS 2 2.01 ?Account? 2 2.02 ?Administrator? 3 2.03 ?Affiliate? 3 2.04 ?Anthem LTIP? 3 2.05 ?Anthem Plan? 3 2.06 ?Anthem SERP? 3 2.07 ?Anthem SERP Par |
|
| July 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE H |
|
| July 20, 2022 |
EXHIBIT 10.2 2017 ELEVANCE HEALTH INCENTIVE COMPENSATION PLAN (JUNE 2022 RESTATEMENT) Anthem, Inc., an Indiana corporation that has changed its name to Elevance Health effective June 28, 2022 (the ?Company?), previously adopted the 2017 Anthem Incentive Compensation Plan, which it hereby amends and restates as the 2017 Elevance Health Incentive Compensation Plan (2022 Restatement) (the ?Plan?), fo |
|
| June 28, 2022 |
Exhibit 3.2 BYLAWS OF ELEVANCE HEALTH, INC. (As Amended June 28, 2022) ARTICLE I Meetings of Shareholders Section 1.1 Annual Meetings. Annual meetings of the shareholders of the Corporation shall be held each year on such date, at such hour and at such place, if any, within or without the State of Indiana, or may be held solely by means of remote communication, as shall be designated by the Board |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 (June 27, 2022) Elevance Health, Inc. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) |
|
| June 28, 2022 |
Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ELEVANCE HEALTH, INC. (As Amended Effective June 27, 2022) The undersigned incorporator, desiring to form a corporation (hereinafter referred to as the ?Corporation?), pursuant to the provisions of the Indiana Business Corporation Law (hereinafter referred to as the ?Corporation Law?), executes the following Articles of Incorporation: A |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 A. Full title of the plan |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 19, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 (May 18, 2022) ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 29, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 (April 26, 2022) ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commis |
|
| April 29, 2022 |
Exhibit 1.1 Execution Version Anthem, Inc. $600,000,000 4.100% Notes due 2032 $700,000,000 4.550% Notes due 2052 UNDERWRITING AGREEMENT Dated: April 26, 2022 TABLE OF CONTENTS Page SECTION 1. Representations and Warranties. 2 SECTION 2. Sale and Delivery to Underwriters; Closing. 11 SECTION 3. Covenants of the Company. 12 SECTION 4. Payment of Expenses. 16 SECTION 5. Conditions of Underwriters? Ob |
|
| April 29, 2022 |
Exhibit 4.2 ANTHEM, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT |
|
| April 29, 2022 |
Exhibit 4.1 ANTHEM, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT |
|
| April 28, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) Anthem, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| April 28, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-249877 PROSPECTUS SUPPLEMENT (To Prospectus dated November 5, 2020) $1,300,000,000 $600,000,000 4.100% Notes due 2032 $700,000,000 4.550% Notes due 2052 The 4.100% Notes due 2032, which we refer to as the 2032 notes, will mature on May 15, 2032 and the 4.550% Notes due 2052, which we refer to as the 2052 notes, will mature on |
|
| April 26, 2022 |
Free Writing Prospectus Filed Pursuant to Rule 433 To Prospectus dated November 5, 2020 Preliminary Prospectus Supplement dated April 26, 2022 Registration Statement File No. |
|
| April 26, 2022 |
Table of Contents This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. |
|
| April 22, 2022 |
ANTHEM REPORTS FIRST QUARTER 2022 RESULTS, REFLECTING STRONG MOMENTUM ACROSS ALL DIVISIONS Exhibit 99.1 PRESS RELEASE ANTHEM REPORTS FIRST QUARTER 2022 RESULTS, REFLECTING STRONG MOMENTUM ACROSS ALL DIVISIONS ? First quarter GAAP net income was $7.39 per share, including net negative adjustment items of $0.86 per share. Adjusted net income was $8.25* per share. ? Operating revenue grew by 18.0% over the prior year quarter to $37.9 billion. ? Operating gain grew by 13.2% over the prior y |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2022 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 20, 2022 |
Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2022. EXHIBIT 10.2(m) Schedule A Notice of Restricted Stock Unit Grant Participant: [?] Company: Anthem, Inc. Notice: You have been granted the following award of restricted stock units of common stock of the Company in accordance with the terms of the Plan and the attached Restricted Stock Unit Award Agreement. Plan: 2017 Anthem Incentive Compensation Plan Grant: Grant Date: [?] Grant Number: [?] Numbe |
|
| April 20, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2022 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 20, 2022 |
ANTHEM REPORTS FIRST QUARTER 2022 RESULTS, REFLECTING STRONG MOMENTUM ACROSS ALL DIVISIONS Exhibit 99.1 PRESS RELEASE ANTHEM REPORTS FIRST QUARTER 2022 RESULTS, REFLECTING STRONG MOMENTUM ACROSS ALL DIVISIONS ? First quarter GAAP net income was $7.39 per share, including net negative adjustment items of $0.86 per share. Adjusted net income was $8.25* per share. ? Operating revenue grew by 18.0% over the prior year quarter to $37.9 billion. ? Operating gain grew by 13.2% over the prior y |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ANTHEM, I |
|
| April 20, 2022 |
Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2022. EXHIBIT 10.2(l) Schedule A Notice of Option Grant Participant: [?] Company: Anthem, Inc. Notice: You have been granted the following nonqualified stock option to purchase shares of common stock of the Company in accordance with the terms of the Plan and the attached Nonqualified Stock Option Award Agreement. Plan: 2017 Anthem Incentive Compensation Plan Grant: Grant Date: [?] Grant Number: [?] Opt |
|
| April 20, 2022 |
Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2022. EXHIBIT 10.2(n) Schedule A Notice of Performance Stock Unit Grant Participant: [?] Company: Anthem, Inc. Notice: You have been granted the following award of performance stock units of common stock of the Company in accordance with the terms of the Plan and the attached Performance Stock Unit Agreement. Plan: 2017 Anthem Incentive Compensation Plan Grant: Grant Date: [?] Grant Number: [?] Number o |
|
| April 1, 2022 | ||
| April 1, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 11, 2022 | ||
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 22, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to certain shares of the Class A common stock of Sera Prognostics, Inc. and further agree that this Joint Filing Agreement shall be i |
|
| February 22, 2022 |
SERA / Sera Prognostics, Inc. Class A / Anthem, Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sera Prognostics, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 81749D107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 16, 2022 |
Exhibit 10.12 BLUE SHIELD LICENSE AGREEMENT (Includes revisions, if any, adopted by Member Plans through their September 23, 2021 meeting) This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Shield Plan, known as (the "Plan"). Preamble WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE SHIELD and B |
|
| February 16, 2022 |
Exhibit 10.11 BLUE CROSS LICENSE AGREEMENT (Includes revisions, if any, adopted by Member Plans through their September 23, 2021 meeting) This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Cross Plan, known as (the "Plan"). Preamble WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE CROSS and BLUE |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ANTHEM, INC. ( |
|
| February 16, 2022 |
EX-21 4 exhibit21-20211231for10xk.htm EX-21 Exhibit 21 SUBSIDIARIES OF THE COMPANY Legal Name Domestic Jurisdiction Doing Business As Advantage Medical Group, LLC Puerto Rico Alianza Medicos del SurEste, LLC Puerto Rico Alliance Care Management, LLC Delaware American Imaging Management, Inc. Illinois AIM Specialty Health AMERIGROUP Community Care of New Mexico, Inc. New Mexico AMERIGROUP Corporati |
|
| February 9, 2022 |
ANTM / Anthem Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Anthem Inc. Title of Class of Securities: Common Stock CUSIP Number: 036752103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| January 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 26, 2022 |
ANTHEM REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS EX-99.1 2 d279540dex991.htm EX-99.1 Exhibit 99.1 ANTHEM REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS • Fourth quarter GAAP net income was $4.63 per share, including net negative adjustment items of $0.51 per share. Adjusted net income was $5.14* per share. • Full year GAAP net income was $24.73 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $25. |
|
| October 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ANTHE |
|
| October 20, 2021 |
ANTHEM REPORTS THIRD QUARTER 2021 RESULTS, RAISES FULL YEAR OUTLOOK EX-99.1 2 d114360dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ANTHEM REPORTS THIRD QUARTER 2021 RESULTS, RAISES FULL YEAR OUTLOOK • Third quarter GAAP net income was $6.13 per share, including net negative adjustment items of $0.66 per share. Adjusted net income was $6.79* per share. • Operating revenue grew by 16.0% over the prior year quarter to $35.5 billion, or 17.5% adjusted for the repeal o |
|
| October 20, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2021 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 (August 3, 2021) ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commis |
|
| August 4, 2021 |
Anthem’s Board Welcomes Susan Dodson DeVore as New Director Exhibit 99.1 Anthem?s Board Welcomes Susan Dodson DeVore as New Director INDIANAPOLIS ? August 4, 2021 ? The Board of Directors of Anthem, Inc. (NYSE: ANTM) announced that Susan Dodson DeVore has joined the Board. Ms. DeVore?s decades of leadership in the healthcare and financial industries demonstrates her focus to create and develop solutions that promote the efficiency and sustainability of hea |
|
| July 21, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2021 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ANTHEM, IN |
|
| July 21, 2021 |
ANTHEM REPORTS SECOND QUARTER 2021 RESULTS, RAISES FULL YEAR OUTLOOK EX-99.1 2 d204038dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE ANTHEM REPORTS SECOND QUARTER 2021 RESULTS, RAISES FULL YEAR OUTLOOK • Second quarter GAAP net income was $7.25 per share, including net positive adjustment items of $0.22 per share. Adjusted net income was $7.03* per share. • Operating revenue grew by 14.1% over the prior quarter to $33.3 billion, or 15.8% adjusted for the repeal of t |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K 11-K 1 antm-12312020x11k.htm FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| June 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 27, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 (May 26, 2021) ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ANTHEM, I |
|
| April 21, 2021 |
EXHIBIT 10.2(m) Schedule A Notice of Option Grant Participant: [?] Company: Anthem, Inc. Notice: You have been granted the following nonqualified stock option to purchase shares of common stock of the Company in accordance with the terms of the Plan and the attached Nonqualified Stock Option Award Agreement. Plan: 2017 Anthem Incentive Compensation Plan Grant: Grant Date: [?] Option Price per Shar |
|
| April 21, 2021 |
ANTHEM REPORTS FIRST QUARTER 2021 RESULTS, RAISES FULL YEAR OUTLOOK Exhibit 99.1 PRESS RELEASE ANTHEM REPORTS FIRST QUARTER 2021 RESULTS, RAISES FULL YEAR OUTLOOK ? First quarter GAAP net income was $6.71 per share, including net negative adjustment items of $0.30 per share. Adjusted net income was $7.01* per share. ? Operating revenue grew by 9.0%, or 10.7% adjusted for the repeal of the health insurance tax, over the prior year quarter to $32.1 billion. ? Medica |
|
| April 21, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 21, 2021 |
EX-10.2(N) 3 exhibit102nanthem2021restr.htm EXHIBIT 10.2(N) EXHIBIT 10.2(n) Schedule A Notice of Restricted Stock Unit Grant Participant: [●] Company: Anthem, Inc. Notice: You have been granted the following award of restricted stock units of common stock of the Company in accordance with the terms of the Plan and the attached Restricted Stock Unit Award Agreement. Plan: 2017 Anthem Incentive Comp |
|
| April 21, 2021 |
EXHIBIT 10.2(o) Schedule A Notice of Performance Stock Unit Grant Participant: [?] Company: Anthem, Inc. Notice: You have been granted the following award of performance stock units of common stock of the Company in accordance with the terms of the Plan and the attached Performance Stock Unit Agreement. Plan: 2017 Anthem Incentive Compensation Plan Grant: Grant Date: [?] Number of Performance Stoc |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 9, 2021 |
2021NoticeofAnnualMeetingof ShareholdersandProxyStatement May26,2021 Indianapolis,INAboutAnthem,Inc. |
|
| April 9, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??????)? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? ? Confidential, For Use of the Commission Only (as permitt |
|
| March 17, 2021 |
Exhibit 1.1 Anthem, Inc. $500,000,000 0.450% Notes due 2023 $750,000,000 1.500% Notes due 2026 $1,000,000,000 2.550% Notes due 2031 $1,250,000,000 3.600% Notes due 2051 UNDERWRITING AGREEMENT Dated: March 8, 2021 TABLE OF CONTENTS Page SECTION 1. Representations and Warranties 2 SECTION 2. Sale and Delivery to Underwriters; Closing 12 SECTION 3. Covenants of the Company 13 SECTION 4. Payment of Ex |
|
| March 17, 2021 |
Exhibit 4.2 ANTHEM, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT |
|
| March 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 (March 8, 2021) ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commiss |
|
| March 17, 2021 |
Exhibit 4.1 ANTHEM, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT |
|
| March 17, 2021 |
Exhibit 4.3 ANTHEM, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT |
|
| March 17, 2021 |
Exhibit 4.4 ANTHEM, INC. THIS GLOBAL SECURITY IS HELD BY AND REGISTERED IN THE NAME OF THE DEPOSITORY (AS DEFINED IN THE INDENTURE GOVERNING THIS SECURITY), IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT |
|
| March 10, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-249877 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Maximum Aggregate Offering Price Amount of Registration Fee (1) 0.450% Notes due 2023 $500,000,000 $54,550 1.500% Notes due 2026 $750,000,000 $81,825 2.550% Notes due 2031 $1,000,000,000 $109,100 3.600% Notes due 2051 $1,250,000,000 $136, |
|
| March 9, 2021 |
Free Writing Prospectus Filed Pursuant to Rule 433 To Prospectus dated November 5, 2020 Preliminary Prospectus Supplement dated March 8, 2021 Registration Statement File No. |
|
| March 8, 2021 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-249877 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell a |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 18, 2021 |
BLUE SHIELD LICENSE AGREEMENT (Includes revisions, if any, adopted by Member Plans through their September 17, 2020 meeting) This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Shield Plan, known as (the "Plan"). |
|
| February 18, 2021 |
Anthem, Inc. Directed Executive Compensation Plan amended effective January 1, 2020 EX-10.6 3 exhibit1062020anthemdirect.htm EXHIBIT 10.6 Summary of the Anthem, Inc. Directed Executive Compensation (DEC) Program (effective January 1, 2020) Directed Executive Compensation (DEC) is an executive perquisite plan that provides officers of Anthem, Inc. (the “Company”) with flexibility to tailor certain benefits to meet their needs with a combination of cash (Cash Credits) and reimburse |
|
| February 18, 2021 |
Description of the Company’s Securities Registered Pursuant to Section 12 of the Exchange Act. EX-4.8 2 exhibit48-2020securitiesex.htm EXHIBIT 4.8 EXHIBIT 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The common stock of Anthem, Inc. (“Anthem,” “we,” “our,” or “us”) is the only class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following is a su |
|
| February 18, 2021 |
EX-10.11 4 exhibit-1011bluecrosslicen.htm EXHIBIT 10.11 BLUE CROSS LICENSE AGREEMENT (Includes revisions, if any, adopted by Member Plans through their September 17, 2020 meeting) This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Cross Plan, known as (the "Plan"). Preamble WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") ha |
|
| February 18, 2021 |
Exhibit 21 SUBSIDIARIES OF THE COMPANY Legal Name Domestic Jurisdiction Doing Business As Alliance Care Management, LLC Delaware American Imaging Management, Inc. |
|
| February 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ANTHEM, INC. ( |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Anthem Inc. Title of Class of Securities: Common Stock CUSIP Number: 036752103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| February 10, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* INDEPENDENCE CONTRACT DRILLING, INC (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 453415309 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 27, 2021 |
ANTHEM REPORTS FOURTH QUARTER AND FULL YEAR 2020 RESULTS EX-99.1 Exhibit 99.1 ANTHEM REPORTS FOURTH QUARTER AND FULL YEAR 2020 RESULTS Indianapolis, Ind.—January 27, 2021—Anthem, Inc. (NYSE: ANTM) reported fourth quarter 2020 results that reflected solid performance across the enterprise. “Despite uncertainties with the pandemic, Anthem delivered strong growth across all of our businesses in 2020 reflecting the diversity and strength of our portfolio an |
|
| November 5, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 5, 2020 Registration No. |
|
| November 5, 2020 |
EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) The Bank of New York Mellon Trust Company, N.A. (Exact name of trustee as specified in its char |
|
| October 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ANTHE |
|
| October 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 ANTHEM, INC. (Exact name of registrant as specified in its charter) Indiana 001-16751 35-2145715 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 28, 2020 |
ANTHEM REPORTS THIRD QUARTER RESULTS REAFFIRMS COMMITMENT TO STAKEHOLDERS DURING COVID-19 PANDEMIC EX-99.1 Exhibit 99.1 PRESS RELEASE ANTHEM REPORTS THIRD QUARTER RESULTS REAFFIRMS COMMITMENT TO STAKEHOLDERS DURING COVID-19 PANDEMIC Indianapolis, Ind. - October 28, 2020 - Anthem, Inc. (NYSE: ANTM) reported third quarter 2020 results that reflect the impacts of ongoing COVID-19 costs and the continued recovery in healthcare utilization while upholding its commitment to addressing financial imbal |
